Advantageous Add-on Duloxetine to Aripiprazole-Responsive Early-Onset Schizophrenia

Pridmore, Saxby; Naguy, Ahmed; Moodliar-Rensburg, Seshni; Alamiri, Bibi

doi:10.1097/jcp.0000000000001313

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Combining an atypical antipsychotic such as aripiprazole and a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) such as duloxetine is found to be advantageous also in early-onset schizophrenia. 5 Both, randomized, double-blind and placebo-controlled trials and meta-analyses showed small but significant effects of duloxetine on reducing negative symptoms and improving general psychopathology in patients with schizophrenia. 6,7 Clayton et al studied the effect of combined treatment of major depressive disorder with aripiprazole and both, SSRI or SSNRI.…”

Section: Introductionmentioning

confidence: 99%

Discovering interactions in augmentation strategies: Impact of duloxetine on the metabolism of aripiprazole

Margraff

Schoretsanitis

Neuner

et al. 2023

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Objective We aimed to unravel potential pharmacokinetic interactions between aripiprazole and duloxetine. Methods Plasma concentrations of aripiprazole in two groups of 78 patients each, receiving aripiprazole as a monotherapy or combined with duloxetine, were compared. A potential impact of duloxetine on the metabolism of aripiprazole was expected in higher plasma concentrations of aripiprazole and higher dose‐adjusted plasma concentrations. Results Patients co‐medicated with duloxetine showed significantly higher plasma concentrations of aripiprazole by 54.2% (p = 0.019). Dose‐adjusted plasma concentrations were 45.6% higher (p = 0.001); 12.8% of these patients exhibited aripiprazole plasma concentrations above the upper limit of the therapeutic reference range, in the control group this was only the case for 10.3% of the patients. A positive relationship was found between the daily dose of duloxetine and dose‐adjusted plasma concentrations of aripiprazole (p = 0.034). As dehydroaripiprazole concentrations were not available, conclusions for the active moiety (aripiprazole plus dehydroaripiprazole) could not be drawn. Conclusions Combining duloxetine and aripiprazole leads to significantly higher drug concentrations of aripiprazole, most likely via an inhibition of cytochrome P450 CYP2D6 and to a lesser extent of CYP3A4 by duloxetine. Clinicians have to consider increasing aripiprazole concentrations when adding duloxetine to a treatment regimen with aripiprazole.

show abstract